ASX ANNOUNCEMENT

ADDITIONAL INFORMATION IN RELATION TO APPENDIX 3B

SYDNEY, Tuesday, 24 January 2012: Cellmid Limited (ASX: CDY) wishes to advise that the attached Appendix 3B form shows the issue of 750,000 ordinary shares in December 2010. These shares were issued on the exercise of options at an exercise price of 3 cents per share. The issue of these shares was not previously reported, but the company can confirm that cumulative totals reported on previous Appendix 3B announcements (such as the number and class of shares quoted and not quoted on the ASX) has been reported correctly.

End

Contact:

Nicholas Falzon, Company Secretary

T +612 9299 0311

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced clinical development program is for the treatment of acute myocardial infarction (AMI) utilising the midkine protein. Cellmid is also developing anti-midkine antibodies for the treatment of inflammatory and autoimmune disorders. In addition, Cellmid is commercialising midkine as a biomarker for cancer diagnosis. Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid's first product, the MK-ELISA, is a blood test that sensitively and accurately measures serum midkine levels.

Midkine (MK)

Midkine is a multifunctional growth factor that is highly expressed during embryonic development. Midkine modulates many important biological interactions such as cell growth, cell migration and cellular adherence. These functions are relevant to cancer, inflammation, autoimmunity, ischemia, nerve growth/repair and wound healing. Midkine is barely detectable in healthy adults and only occurs as a consequence of the pathogenesis of a number of different disorders. Midkine expression is often evident very early in disease onset, even before any apparent physical symptoms. Accordingly, midkine is an important early marker for diagnosing cancers and autoimmune diseases. Finally, because midkine is only present in a disease context, targeting midkine does not harm normal healthy tissues.

CELLMID LIMITED ACN 111 304 119 ASX I CDY

Level 6, 40 King Street, Sydney NSW 2000 AUSTRALIA TELEPHONE +61 2 9299 0311 FACSIMILE +61 2 9299 2198

WEB www.cellmid.com.au

Appendix 3B

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003.

Name of entity: CELLMID LIMITED

ABN: 69 111 304 119

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued

(CDY) - Ordinary Shares (CDY1) - Ordinary Shares (CDY2) - Ordinary Shares

2 Number of +securities issued or to be issued (if known) or maximum number which may be issued

(CDY) - 1,666,667 (CDY1) - 750,000 (CDY2) - 22,500

3 Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid

+securities, the amount outstanding

and due dates for payment; if

+convertible securities, the conversion price and dates for conversion)

(CDY) - Fully paid ordinary shares (CDY1) - Fully paid ordinary shares (CDY2) - Fully paid ordinary shares

+ See chapter 19 for defined terms.

Appendix 3B Page 1

4 Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted

+securities?

If the additional securities do not rank equally, please state: